Wedbush Increases Earnings Estimates for Ascendis Pharma A/S
Analysts at Wedbush upped their FY2029 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued to investors on Wednesday, February 12th. Wedbush analyst Y. Zhong now ...
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $225.00
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $200.00 to $225.00 in a research note issued to investors on Thursday,Benzinga reports.
Analysts Set Expectations for Expro Group FY2024 Earnings
Equities research analysts at Sidoti Csr decreased their FY2024 earnings per share (EPS) estimates for shares of Expro Group in a note issued to investors on Thursday, February 13th. Sidoti Csr ...